Medtronic’s investment is contingent on Anteris completing a proposed $200 million public stock offering.

Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.

The Medtronic investment and the underwritten public offering of common stock position Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform ...

KUWAIT CITY, Jan 24: Kuwait’s Ministry of Health announced on Saturday the successful completion of the world’s first ...

A federal judge has paused the merger of the only two companies developing a heart device made for high-risk patients suffering from ...

PLYMOUTH MEETING, Pa. (WPVI) -- The TAVR procedure has revolutionized a challenging task in heart care: fixing stiff valves. And it has made the process much easier for patients, getting them back to ...

The global TAVR embolic protection market is experiencing steady growth, with revenue estimated to increase from approximately $124 million in 2023 to around $403 million by 2032. This growth, driven ...

Anteris Technologies says Medtronic will make a strategic investment of up to $90 million in the transcatheter heart valve ...

Please provide your email address to receive an email when new articles are posted on . A new generation of a balloon-expandable transcatheter aortic valve replacement system reduced paravalvular leak ...

St. Luke’s Medical Center - Global City marks a significant milestone for its cardiovascular services, having successfully ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. An intra-annular self-expanding transcatheter heart ...

Delirium is more common in patients undergoing surgical rather than transcatheter aortic valve replacement (SAVR, TAVR) but predicted worse in-hospital outcomes after both procedures, a new study ...